The CEO of pharma giant Mylan might need some strong medication of her own after getting a congressional beat down.

Mylan chief Heather Bresch and her company were accused of "disgusting" greed and of getting "filthy rich" by congressmen as she sought to defend the company's decision to hike the price of lifesaving anti-allergy EpiPens by more than 500 percent in recent years.

"The greed is astounding, it's sickening and disgusting," Rep. John Duncan, R-Tenn., told Bresch as she was grilled by members of the House Oversight and Government Reform Committee over the now-more-than $600 price for a two-pack of EpiPens.

"I'm a very conservative, pro-business Republican, but I am really sickened by what I heard today, and what I've read before about this situation," Duncan said.

"In my opinion, no one can really earn or deserve $19 million a year," said Duncan, referring to an amount close to what Bresch made last year.

Bresch, started the hearing by arguing that the company isn't making profits that come close to the more than $600 sticker price.

"I'm proud to be the CEO of Mylan, but I never expected to be here under these circumstances — discussing the price of EpiPen Auto-Injectors," Bresch told the committee.

"I've spent my entire career working to break down barriers, expand access to high-quality medicines and lower health-care costs," said Bresch, whose company has increased the price of EpiPens more than 500 percent in recent years.

"It troubles me greatly that the EpiPen product has become a source of controversy," said Bresch, 47, whose father is U.S. Sen. Joe Manchin, D-W. Va.